Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eloise Salmon

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Expert Opinion on Pharmacotherapy|April 15, 2025
Emerging pharmacotherapies for the treatment of childhood nephrotic syndromeEloise Salmon, Howard Trachtman
Pediatric Nephrology (Berlin, Germany)|December 27, 2024
Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN databaseKelly Garrity, Nathaniel Putnam, Elaine S Kamil, et al.
Kidney360|July 18, 2022
The Health Economic Impact of Nephrotic Syndrome in the United StatesChristine A Simon, Eloise Salmon, Hailey E Desmond, et al.
Journal of the American Society of Nephrology : JASN|January 21, 2026
Patient-Focused Drug Development in Kidney Disease: Including Fit-for-Purpose Outcomes in TrialsJohn Devin Peipert, Louise Oni, Olalekan Lee Aiyegbusi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2026
How much change is meaningful in global impression anchors? Evidence from five rare diseasesCourtney Hurt, Maja Kuharic, Somayeh Hashemi, et al.
Critical Care Explorations|March 14, 2020
Vecuronium- and Esmolol-Induced Pseudohypernatremia Due to Drug Interference With Ion-Selective ElectrodesTracey G Polsky, Eloise Salmon, Sarah S Welsh, et al.
Glomerular Diseases|May 11, 2026
Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial DesignJohn Devin Peipert, Maja Kuharic, Noelle E Carlozzi, et al.
Glomerular Diseases|October 30, 2024
Preparation and Rationale for a Patient-Centered Clinical Outcome Assessment Set of Fluid Overload for Drug Development in Nephrotic SyndromeEloise Salmon, Noelle E Carlozzi, Jin-Shei Lai, et al.
Glomerular Diseases|February 13, 2024
FSGS Recurrence Collaboration: Report of a SymposiumDebbie S Gipson, Chia-Shi Wang, Eloise Salmon, et al.
Kidney International|February 26, 2026
Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic SyndromeTiffany Tu, Alejandro Ochoa, Amika Sood, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|April 15, 2025
Emerging pharmacotherapies for the treatment of childhood nephrotic syndromeEloise Salmon, Howard Trachtman
Pediatric Nephrology (Berlin, Germany)|December 27, 2024
Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN databaseKelly Garrity, Nathaniel Putnam, Elaine S Kamil, et al.
Kidney360|July 18, 2022
The Health Economic Impact of Nephrotic Syndrome in the United StatesChristine A Simon, Eloise Salmon, Hailey E Desmond, et al.
Journal of the American Society of Nephrology : JASN|January 21, 2026
Patient-Focused Drug Development in Kidney Disease: Including Fit-for-Purpose Outcomes in TrialsJohn Devin Peipert, Louise Oni, Olalekan Lee Aiyegbusi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2026
How much change is meaningful in global impression anchors? Evidence from five rare diseasesCourtney Hurt, Maja Kuharic, Somayeh Hashemi, et al.
Critical Care Explorations|March 14, 2020
Vecuronium- and Esmolol-Induced Pseudohypernatremia Due to Drug Interference With Ion-Selective ElectrodesTracey G Polsky, Eloise Salmon, Sarah S Welsh, et al.
Glomerular Diseases|May 11, 2026
Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial DesignJohn Devin Peipert, Maja Kuharic, Noelle E Carlozzi, et al.
Glomerular Diseases|October 30, 2024
Preparation and Rationale for a Patient-Centered Clinical Outcome Assessment Set of Fluid Overload for Drug Development in Nephrotic SyndromeEloise Salmon, Noelle E Carlozzi, Jin-Shei Lai, et al.
Glomerular Diseases|February 13, 2024
FSGS Recurrence Collaboration: Report of a SymposiumDebbie S Gipson, Chia-Shi Wang, Eloise Salmon, et al.
Kidney International|February 26, 2026
Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic SyndromeTiffany Tu, Alejandro Ochoa, Amika Sood, et al.
Pageof 2